1-6 of 6
Ingo Schwaner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes of CLL Patients Treated with Venetoclax Under Real-World Conditions in Austria, Germany, and Switzerland after Treatment with Ibrutinib

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi
Journal: Blood
Blood (2024) 144 (Supplement 1): 6788.
https://doi.org/10.1182/blood-2024-200644
Published: 2024
Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Noesslinger, Julia Von Tresckow, Ruediger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Gärtner, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Ursula Vehling-Kaiser, Matthias Ritgen, Christian Spoer, Michael J. Eckart, Thomas Decker, Geothy Chakupurakal, Björn Schöttker, Jens Kisro, Janina Stumpf, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2024) 144 (Supplement 1): 4618.
https://doi.org/10.1182/blood-2024-200848
Published: 2024
Journal Articles

Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting

Katia Pini, Alessio Bruscaggin, Maria Cristina Pirosa, Gabriela Forestieri, Joyce Marques de Almeida, Georg Stüssi, Mathias Oertli, Xenia Schmidt, Johannes Huelsenbeck, Thomas Noesslinger, Ingo Schwaner, Monica Gallucci, Heidi Simmons, Davide Rossi, Adalgisa Condoluci
Journal: Blood
Blood (2023) 142 (Supplement 1): 3257.
https://doi.org/10.1182/blood-2023-180509
Published: 2023
Journal Articles

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi
Journal: Blood
Blood (2023) 142 (Supplement 1): 4654.
https://doi.org/10.1182/blood-2023-174387
Published: 2023
Journal Articles

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

Ingo Schwaner, Holger Hebart, Christoph Losem, Thomas Wolff, Kirsten Famulla, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi, Thomas Noesslinger
Journal: Blood
Blood (2022) 140 (Supplement 1): 12412–12413.
https://doi.org/10.1182/blood-2022-162273
Published: 2022
Journal Articles

Safety and Effectiveness of Venetoclax/Rituximab in Bcri-Naïve and Bcri-Exposed Patients with Relapsed/Refractory CLL Under Real-Life Conditions - Data from the Observational Verve Study

Davide Rossi, Holger Hebart, Christoph Losem, Thomas Wolff, Xenia Schmidt, Kirsten Famulla, Burkhard Schmidt, Thomas Noesslinger, Ingo Schwaner
Journal: Blood
Blood (2021) 138 (Supplement 1): 3735.
https://doi.org/10.1182/blood-2021-145555
Published: 2021